NEW YORK, Feb. 08, 2021 (World NEWSWIRE) — Anavex Lifestyle Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a scientific-stage biopharmaceutical business creating differentiated therapeutics for the remedy of neurodegenerative and neurodevelopmental conditions like Alzheimer’s disease, Parkinson’s disorder, Rett syndrome and other central nervous procedure (CNS) disorders, currently declared that it will issue financial effects for its fiscal quarter ended December 31, 2020 on Thursday, February 11, 2021.
Administration will host a conference phone on Thursday, February 11, 2021 at 4:30 pm Japanese Time to assessment money effects and supply an update on its scientific programs and corporate highlights. Subsequent management’s formal remarks, there will be a concern-and-solution session with fairness analysts.
Conference Contact / Webcast Info:
The live webcast of the convention simply call can be accessed on-line at https://wsw.com/webcast/cc/avxl17/1498482.
To join the convention phone, reside by means of phone, fascinated get-togethers in the U.S. must dial, toll-absolutely free, 1 (866) 451-7964 and international callers should really dial 1 (847) 944-7134. Please use confirmation range 50097999, adopted by the pound indication (#).
A replay of the conference phone will also be available on www.anavex.com.
About Anavex Existence Sciences Corp.
Anavex Lifetime Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company devoted to the growth of differentiated therapeutics for the therapy of neurodegenerative and neurodevelopmental diseases like Alzheimer’s disorder, Parkinson’s ailment, Rett syndrome and other central nervous procedure (CNS) health conditions, ache and many forms of most cancers. Anavex’s direct drug candidate, ANAVEX®2-73 ( blarcamesine ), lately completed properly a Stage 2a scientific trials for Alzheimer’s disorder and a Section 2 proof-of-notion review in Parkinson’s condition dementia and a Period 2 analyze in adult patients with Rett syndrome. ANAVEX®2-73 is an orally readily available drug prospect that restores mobile homeostasis by concentrating on sigma-1 and muscarinic receptors. Preclinical reports shown its opportunity to halt and/or reverse the program of Alzheimer’s illness. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant houses in animal models, indicating its prospective to take care of added CNS diseases, which include epilepsy. The Michael J. Fox Foundation for Parkinson’s Analysis beforehand awarded Anavex a research grant, which absolutely funded a preclinical review to produce ANAVEX®2-73 for the cure of Parkinson’s illness. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising scientific phase drug applicant demonstrating disease-modifying exercise in opposition to the significant hallmarks of Alzheimer’s ailment in transgenic (3xTg-Advert) mice, which includes cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has demonstrated effective outcomes on mitochondrial dysfunction and neuroinflammation. Additional facts is readily available at www.anavex.com. You can also connect with the company on Twitter,Fb and LinkedIn.
Statements in this press launch that are not strictly historical in nature are ahead-searching statements. These statements are only predictions dependent on current facts and expectations and include a selection of pitfalls and uncertainties. Genuine gatherings or outcomes could differ materially from these projected in any of such statements owing to numerous variables, together with the risks established forth in the Company’s most current Yearly Report on Sort 10-K submitted with the SEC. Readers are cautioned not to area undue reliance on these ahead-hunting statements, which speak only as of the date hereof. All ahead-on the lookout statements are skilled in their entirety by this cautionary statement and Anavex Daily life Sciences Corp. undertakes no obligation to revise or update this press launch to mirror functions or conditions right after the day hereof.
For Even further Data:
Anavex Life Sciences Corp.
Research & Business Improvement
Toll-no cost: 1-844-689-3939
Electronic mail: [email protected]
Andrew J. Barwicki
Email: [email protected]